The escalating conflict in Iran is causing significant disruption to the pharmaceutical supply chain, leading to soaring medicine prices and potential shortages of life-saving drugs for British cancer patients and those with other conditions. Experts warn of a worsening crisis impacting access to essential treatments.

Impact on Cancer Treatment

The health of British cancer patients is facing a significant threat as the conflict triggers a dramatic surge in medicine prices and widespread supply chain disruptions. This impacts not only cancer treatments themselves but also medications used to manage symptoms and mitigate side effects.

Existing NHS Shortages Exacerbated

This crisis builds upon existing shortages within the National Health Service (NHS), which have been further exacerbated by the conflict’s impact on crucial air freight routes and the subsequent increase in fuel and shipping costs. Pharmacies are reporting receiving only a quarter of their usual drug volumes.

Price Increases Reported

A recent survey by the National Pharmacy Association (NPA), encompassing 400 pharmacies across the United Kingdom, revealed that all respondents have experienced price increases in commonly prescribed medications. Some drugs have seen prices skyrocket by as much as eleven-fold since February.

Department of Health Response

The Department of Health and Social Care (DHSC) has issued price concessions – temporary increases in reimbursement rates to pharmacies – but these concessions have reached their highest level in years. Some pharmacies are already reporting financial losses, as NHS reimbursement falls short of acquisition costs.

Concerns for Future Supply

Olivier Picard, chairman of the NPA, emphasized the potential for further deterioration if the conflict and associated blockade persist. He highlighted that medicine shortages have become increasingly commonplace in recent years.

Critical Drug Shortages

Several critical cancer treatments are already experiencing shortages, including Creon (pancreatic cancer), Efudix (skin cancers), and intravenous drugs like Endoxan, Sendoxan, and Genoxal (breast, lung, ovarian cancer, lymphoma, leukaemia, and myeloma). The NHS has not yet issued formal shortage notices for these drugs, but disruption is imminent.

Rising Transport and Raw Material Costs

Mark Samuels, chief executive of Medicines UK, warned that transport costs have surged by up to 300 percent. The conflict is also disrupting the supply of critical raw materials, many of which are petrochemicals reliant on passage through the Strait of Hormuz. Rising fossil fuel costs are also contributing to increased manufacturing expenses.

Impact on Generic Medications

Given that off-patent medicines constitute the vast majority of treatments used by NHS patients, the likelihood of shortages and price increases in the coming weeks is substantial. This disruption will directly impact patients across the NHS, affecting essential treatment areas such as cancer care, pain relief, antibiotics, and mental health.

Recent Medication Shortages

The current crisis follows recent warnings regarding supply issues affecting everyday medications, including Ramipril, a common high blood pressure drug, for which a ‘serious shortage protocol’ has been issued. The situation demands urgent attention and proactive measures to safeguard the availability of essential medicines.